Prostate Cancer News on BioPortfolio

Corcept Therapeutics Q32018 Results & Guidance BioWatch Commentary

On Thursday November 1 2018 Corcept Therapeutics CORT reportedits Q32018 results and held a conference call. After the call we talked briefly with IR Director Christopher James to clarify fine details on the extant science. Recent HighlightsJudge Denies Te...

Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 Pipeline Review H2 2018 Report Updated 16102018 Prices from USD $3500

Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 Pipeline Review H2 2018SummaryTumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T C...

Carrier blocks using gold in biomedicine

This can be taken advantage of by a conjugation to biomolecules enabled by the chemical affinity of gold to thiol groups biomolecules such as peptides oligonucleotides or antibodies can be attached to gold surfaces by using covalent thiol bonding with or w...

European Commission approves enzalutamide for highrisk nmCRPC

The European Commission EC has approved a new indication for enzalutamide for the treatment of adult men with highrisk nonmetastatic castrationresistant prostate cancer nmCRPCÂbased on the results from the pivotal phase 3 PROSPER trial.This...

Hardman & Co Research ValiRx VAL VAL401 Phase II trial completed

Hardman & Co Research01Nov2018 0715 GMTBSTHardman & Co VAL401 Phase II trial completedValiRx VAL is a clinicalstage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company's two leading ass...

Pages